Symrise in advanced talks to divest terpenes business

Symrise (SYIEY) is in advanced talks with potential interested parties about the sale of its terpenes business. This is a structured bidding process. Based on the offers received so far, the international accounting standard IFRS 5 will be applied. In this context, a non-cash impairment charge of approximately EUR 145M is recorded in the fourth quarter of 2025. This has a negative impact on Symrise AG’s EBIT, the company said. According to preliminary calculations, a non-cash impairment in the value of the investment in Sweden-listed Swedencare AB (SWDCF) will lead to a material deviation from the expected result for the 2025 financial year compared to current capital market expectations and the published forecast. Symrise AG will record a non-cash impairment charge of the investment in Swedencare AB in the amount of EUR 150M in the fourth quarter of 2025. This has a negative impact on EBITDA.